Business
Director/PDMR Shareholding
Director/PDMR Shareholding.
About this update from Ekf Diagnostics Holdings Plc
[{"type":"text","content":"\n\nEKF Diagnostics Holdings plc\n(\"EKF\", the \"Company\" or the \"Group\")\n \nPDMR/Director Dealings\n \nEKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that on Tuesday 25 March 2025, the following members of the EKF Board purchased 550,000 ordinary shares of 1 pence each in the Company (\"Ordinary Shares\") at a price of 22.0 pence per Ordinary Share:\n \n \n\n\n\n\nDirector\n\n\nTitle\n\n\nNumber of Ordinary Shares purchased\n\n\nResulting holding in Ordinary Shares\n\n\nPercentage of issued share capital\n\n\n\n\nJulian Baines\n\n\nExecutive Chair\n\n\n50,000\n\n\n1,666,288\n\n\n0.37%\n\n\n\n\nGavin Jones\n\n\nChief Executive Officer\n\n\n50,000\n\n\n50,000\n\n\n0.01%\n\n\n\n\nStephen Young\n\n\nChief Financial Officer\n\n\n50,000\n\n\n135,000\n\n\n0.03%\n\n\n\n\nChristopher Mills¹\n\n\nNon-Executive Director\n\n\n150,000\n\n\n133,500,000 \n\n\n29.42%\n\n\n\n\nChristian Rigg\n\n\nNon-Executive Director\n\n\n100,000\n\n\n100,000\n\n\n0.02%\n\n\n\n\nJennifer Winter\n\n\nNon-Executive Director\n\n\n150,000\n\n\n150,000\n \n\n\n0.03%\n\n\n\n\n \n¹Includes direct and indirect interests in the Company\n \n \n\n\n\n\nEKF Diagnostics Holdings plc\n\n\nwww.ekfdiagnostics.com\n\n\n\n\nJulian Baines, Executive Chair\n\n\n Tel: +44 (0)29 2071 0570\n\n\n\n\n\n\n\n\n\n\n\n\nSinger Capital Markets (Nominated Adviser & Broker)\n\n\nTel: +44 (0)20 7496 3000\n\n\n\n\nPhil Davies / Oliver Platts\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Alice Woodings\n\n\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\n\n\n\n\n\n\n\n\n\n\n \nAbout EKF Life Sciences\n \nEKF Life Sciences is a specialist global manufacturer of high-quality enzymes and custom products for use in diagnostic, pharmaceutical, and industrial applications.\n \nEKF Life Sciences is at the forefront of supporting global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver advancements in healthcare and medicine.\n \nUtilising its unique technical expertise, the EKF Life Sciences uses precision microbial fermentation and advanced downstream processes to isolate and deliver the highest quality enz...